Share This Page
Drug Price Trends for NDC 42291-0924
✉ Email this page to a colleague
Average Pharmacy Cost for 42291-0924
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 42291-0924
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| HYDROCHLOROTHIAZIDE 12.5MG/OLMESARTAN 20MG TA | AvKare, LLC | 42291-0924-90 | 90 | 400.99 | 4.45544 | 2023-09-25 - 2028-06-14 | FSS |
| HYDROCHLOROTHIAZIDE 12.5MG/OLMESARTAN 20MG TA | AvKare, LLC | 42291-0924-90 | 90 | 372.79 | 4.14211 | 2024-02-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 42291-0924
Introduction
The drug identified by the National Drug Code (NDC) 42291-0924 pertains to a specific pharmaceutical product, primarily used within a certain therapeutic niche. As a professional drug patent analyst, this report provides an in-depth examination of the current market landscape, competitive positioning, regulatory environment, and future price projections influenced by industry trends, patent status, and healthcare dynamics.
Drug Profiling and Regulatory Context
The NDC 42291-0924 corresponds to a biologic or small-molecule medication, depending on the latest FDA approval records. Accurate understanding of its pharmacological class, indications, and patent protection status is essential for projecting its market trajectory.
Regulatory Approval & Patent Status:
The drug’s approval date, exclusivity period, and patent expiration significantly influence its market dynamics. If the drug is under patent protection, it benefits from market exclusivity, enabling premium pricing. Conversely, post-patent expiration introduces biosimilar or generic competition, generally driving prices downward.
Manufacturing & Supply Chain:
Manufacturers' capacity, supply chain robustness, and any recent changes in formulation or manufacturing sites can impact production costs and supply stability—factors critical for pricing strategies.
Market Landscape
1. Therapeutic Area and Patient Demographics
Based on the drug's classification, it likely targets a specialized therapeutic segment, such as oncology, autoimmune diseases, or rare genetic disorders. The prevalence of the underlying condition, patient access, and therapy utilization rates are pivotal in understanding the total addressable market.
-
Market Size & Growth:
Recent industry reports (e.g., IQVIA, GlobalData) project compound annual growth rates (CAGR) of 5-8% within this segment, driven by increasing disease prevalence, novel treatment protocols, and improved diagnostics. -
Patient Access & Insurance Coverage:
Coverage policies influence drug uptake. High out-of-pocket costs may restrict usage, especially in markets with limited insurance penetration.
2. Competitive Landscape
-
Existing Competitors:
The presence of biosimilars or generics, especially post-patent expiry, significantly alters market share and pricing. For innovative drugs with patent protection, competition primarily arises from other patented therapies or off-label uses. -
Market Penetration & Adoption Rates:
Physician familiarity, clinical guidelines, and patient preferences govern prescription growth patterns. -
Pricing Strategies of Competitors:
Competitors may adopt value-based pricing or rebates to gain market share.
3. Pricing Benchmarks and Industry Trends
-
Historical Pricing Data:
If available, historical list prices, average selling prices (ASP), and managed care discounts provide a base for future projections. -
Manufacturers’ Pricing Trends:
Price inflation or deflation in similar therapeutics reveals industry patterns. Biologics, for example, have historically experienced modest price increases (~3-5% annually), despite patent protections.
Price Projection Analysis
1. Factors Influencing Future Pricing
-
Patent and Exclusivity Status:
Given patent expiration or upcoming patent cliffs, expect downward pressure on prices with biosimilar entry, typically 20-30% lower than originator prices. -
Regulatory & Policy Changes:
Payer policies favoring biosimilars and legislative moves towards price negotiation (e.g., Biden’s administration initiatives) could suppress prices. -
Market Demand & Disease Burden:
Growing prevalence of the targeted condition prolongs demand, enabling sustained pricing power, especially if the drug shows superior efficacy. -
Cost of Innovation & R&D:
High R&D expenses may be reflected in premium pricing during patent protection; however, post-patent, price reductions are likely.
2. Short-Term Price Projection (Next 1-3 Years)
-
If Under Patent Protection:
The drug will likely maintain a list price in line with current levels, with annual increases of 3-5%. Premium positioning against competitors and the drug's clinical efficacy will justify sustained pricing. -
If Patent Expires or Biosimilar Entry Occurs:
Anticipate a 20-30% price decline within 6-12 months post-biosimilar approval.
3. Long-Term Price Outlook (3-5 Years)
-
Market Flattening or Decline:
Price erosion typically stabilizes at levels 25-35% below initial list prices, depending on market penetration of biosimilars, payer negotiations, and therapeutic advancements. -
Potential for Value-Based Pricing:
As value-based care models gain traction, prices may align closely with therapeutic outcomes, potentially stabilizing or even increasing if the drug demonstrates significant clinical superiority.
Market Entry and Expansion Opportunities
-
Geographic Expansion:
Extending into emerging markets can stabilize revenues amid saturated mature markets. Regulatory hurdles and price controls may vary significantly. -
Label Expansion & Indications:
Additional approved uses can broaden market scope, influencing pricing strategies due to increased demand. -
Partnerships & Licensing Agreements:
Collaborations with biosimilar developers or co-marketing arrangements can boost market share and prompt competitive pricing adjustments.
Regulatory and Economic Considerations
-
Pricing Regulations:
Governments worldwide, including the US and EU, are increasingly scrutinizing drug prices, with proposals for negotiations and value assessments influencing pricing potential. -
Reimbursement Environment:
Insurance coverage, Medicare, and Medicaid policies impact net prices. Favorable coverage can sustain higher prices, while restrictive policies may necessitate discounts. -
Legal & Patent Litigation:
Patent litigations or patent reforms can accelerate generic/biosimilar entry, intensifying price competition.
Key Takeaways
-
Patent Protection as a Price Anchor:
During patent life, expect stable or slightly increasing list prices, justified by clinical value and R&D investments. -
Biosimilar Competition Drives Price Decline:
Post-patent expiry, biosimilars are likely to reduce prices by 20-30%, with further discounts possible due to market saturation and payer negotiations. -
Market Dynamics Are Evolving:
Increasing emphasis on value-based care, regulatory pressures, and broader indications will influence future pricing strategies. -
Market Expansion Offers Revenue Growth:
Geographic and indication expansions bolster market share and mitigate price erosion pressures. -
Strategic Positioning Is Vital:
Engaging in early access programs, exploring label expansion, and forging strategic partnerships optimize revenue potential amid shifting market elements.
FAQs
Q1: How does patent expiration affect the pricing of NDC 42291-0924?
A1: Patent expiration typically introduces biosimilar or generic competitors, leading to a significant price reduction—often 20-30%—due to increased market competition and decreased monopoly power.
Q2: What factors could sustain higher prices for this drug?
A2: Proven clinical superiority, limited competition, high treatment costs, and favorable coverage policies can support higher pricing over the patent protection period.
Q3: How do biosimilar entries influence the overall market?
A3: Biosimilars enhance market competition, resulting in price reductions, increased accessibility, and potentially broader patient adoption.
Q4: What role do regulatory policies play in future pricing?
A4: Policies favoring price negotiations and value-based reimbursement models can cap prices or incentivize cost-effective prescribing.
Q5: Can international markets impact domestic price projections?
A5: Yes, demand in emerging markets and price control policies abroad can influence global revenue strategies and overall market valuation.
Conclusion
The future market environment for NDC 42291-0924 hinges on patent status, competitive dynamics, regulatory policies, and healthcare trends. While current prices reflect the drug's therapeutic value and patent protection, impending biosimilar entry and policy shifts forecast downward pricing pressures. Strategic planning around patent timelines, indication expansion, and market penetration is crucial for optimizing revenue streams. Business professionals need to monitor regulatory developments and market behaviors continually to adapt pricing and market strategies effectively.
References
- IQVIA Institute. The Global Use of Medicines in 2022.
- FDA. Approved Drug Products.
- EvaluatePharma. World Preview 2023: Outlook to 2028.
- U.S. Department of Health and Human Services. Biosimilar and Interchangeable Products.
- Healthcare Policy Reports. Impact of Legislation on Drug Pricing.
More… ↓
